ArticleJournal of ovarian research2026
CC223 enhances cisplatin sensitivity of platinum-resistant ovarian cancer by inducing cell cycle arrest.
Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPlatinum-based chemotherapy is the standard treatment for ovarian cancer. However, the emergence of platinum resistance greatly limits its effectiveness. Investigating novel therapeutic strategies to overcome platinum resistance is imperative to extend survival in ovarian cancer patients.
methodsThe cytotoxic effects of CC223 on SKOV3DDP and A2780DDP were evaluated using the CCK8 assay. Based on the ovarian cancer organoid model, drug screening testing was employed to assess the sensitivity of ovarian cancer to CC223. The impact of CC223 on the biological behaviors of SKOV3DDP and A2780DDP was evaluated using colony formation, migration, and invasion assays. The synergistic effect of CC223 and cisplatin was analyzed by combining the CCK8 assay with SynergyFinder software (ZIP score). Concurrently, the difference in drug response between the CC223-cisplatin combination and cisplatin monotherapy was validated using cell lines, organoids, and tumor xenograft models. The activation status of the AKT-mTOR pathway was detected by immunohistochemistry and western blotting in ovarian cancer cell lines and organoids, while flow cytometry analysis was used to assess the effect of the CC223-cisplatin combination on the cell cycle.
resultsWe found that CC223 could exert a killing effect on platinum-resistant ovarian cancer cells and organoids. CC223 suppressed the proliferation, migration and invasion of platinum-resistant ovarian cancer cells in a dose-dependent manner. Moreover, the combined treatment with CC223 and cisplatin exhibited synergistic anti-proliferative effects in vitro and in vivo. In patient-derived organoids(PDOs) of ovarian cancer, we found enhanced mTOR activation, and the PDOs-guided drug sensitivity analysis revealed that CC223 could enhance sensitivity to cisplatin. Hyperactivation of mTOR signaling in platinum-resistant ovarian cancer cells leads to the poor prognosis of ovarian cancer patients. CC223 could potently suppress the aberrantly activated AKT-mTOR pathway in platinum-resistant ovarian cancer cells. Furthermore, the combined therapy of CC223 and cisplatin can affect cell proliferation by arresting the G0/G1 phase.
conclusionOur study demonstrated that CC223 could enhance the sensitivity of cisplatin by effectively inhibiting the activation of the AKT-mTOR pathway and potentially arresting the G0/G1 phase. These findings suggest that the synergistic effect of CC223 and cisplatin holds promise as a potential therapeutic strategy for platinum-resistant ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.